Pronostic and Predictive Value of EMT in Localized Lung Cancer
Launched by EUROPEAN GEORGES POMPIDOU HOSPITAL · Apr 17, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a specific biological feature called the "EMT signature" to see if it can help predict long-term survival for patients with non-small cell lung cancer (NSCLC) after surgery. Researchers hope that by studying different genetic markers in the tumors of patients with early to advanced stages of lung cancer, they can develop better treatment recommendations tailored to individual patients. The study is currently recruiting participants who are between the ages of 65 and 74 and have undergone surgery for NSCLC at Georges Pompidou Hospital.
To be eligible for this trial, patients must have been diagnosed with NSCLC at stages I, II, IIIA, or IIIB and have signed an informed consent form. If you join the study, you can expect to provide samples of your tumor for analysis so researchers can identify important markers that may help improve future treatments. This research could lead to significant advancements in understanding lung cancer and how to treat it more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with NSCLC stage I II IIIA IIIB, treated by surgery at Georges Pompidou Hospital (HEGP) Informed consent ONCOHEGP signed
- Exclusion Criteria:
- • Informed consent ONCOHEGP not signed
About European Georges Pompidou Hospital
The European Georges Pompidou Hospital (Hôpital Européen Georges-Pompidou, HEGP) is a leading healthcare institution located in Paris, France, dedicated to providing high-quality medical care and advancing medical research. As a prominent clinical trial sponsor, HEGP is committed to facilitating innovative research initiatives that enhance patient outcomes and contribute to the global medical community. With a multidisciplinary approach, HEGP collaborates with renowned researchers and healthcare professionals to conduct clinical trials across various therapeutic areas, ensuring adherence to rigorous ethical standards and regulatory compliance. The hospital's state-of-the-art facilities and expertise in patient care position it as a key player in the advancement of medical science and the translation of research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Francoise Lepimpec Barthes, MD PhD
Principal Investigator
APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials